7.2 Medications for Addiction Treatment (MAT/MOUD) and Pharmacotherapies

Medications for Addiction Treatment (MAT/MOUD) and Pharmacotherapies

Pharmacotherapy in substance use disorder treatment represents an essential, evidence-based pillar of modern addiction medicine. Chronic substance exposure induces profound neurobiological adaptations within the mesocorticolimbic dopamine pathway, the extended amygdala (stress neurocircuitry), and the prefrontal cortex (executive function and impulse control). Medications for Addiction Treatment (MAT), specifically Medications for Opioid Use Disorder (MOUD) and Alcohol Use Disorder (AUD) pharmacotherapies, restore neurochemical homeostasis, eliminate debilitating physical withdrawal, suppress compulsive cravings, and block the reinforcing euphoric effects of substance misuse.

Addiction counselors must possess comprehensive pharmacological knowledge to educate clients, dispel widespread societal and peer-recovery stigma (e.g., the harmful myth that medication is merely "trading one drug for another"), support treatment adherence, recognize adverse effects, and collaborate effectively with prescribing medical providers.

---

1. Receptor Neurobiology: Agonists, Partial Agonists, and Antagonists

To understand MOUD and AUD medications, counselors must master the pharmacological concepts of binding affinity (how strongly a molecule binds to a receptor) and intrinsic activity / efficacy (the degree of biological response or cellular activation triggered by that binding).

+-----------------------------------------------------------------------------+
|                   RECEPTOR PHARMACOLOGY CLASSIFICATIONS                     |
|                                                                             |
|   [FULL AGONIST] (e.g., Methadone, Morphine, Heroin, Oxycodone)             |
|   • High Binding Affinity + 100% Intrinsic Activity                         |
|   • Activates receptor fully; dose-dependent response with NO ceiling effect|
|   • High risk of respiratory depression at elevated doses                   |
|                                                                             |
|   [PARTIAL AGONIST] (e.g., Buprenorphine, Varenicline)                      |
|   • VERY HIGH Binding Affinity + Moderate (~30-50%) Intrinsic Activity      |
|   • Activates receptor partially; CEILING EFFECT on respiratory depression  |
|   • Displaces full agonists from receptors (Precipitated Withdrawal Risk)   |
|                                                                             |
|   [ANTAGONIST] (e.g., Naloxone, Naltrexone)                                 |
|   • High Binding Affinity + ZERO (0%) Intrinsic Activity                    |
|   • Occupies and "blocks" receptor without activating it                    |
|   • Completely blocks agonists; reverses overdose or prevents euphoria      |
+-----------------------------------------------------------------------------+

---

2. Medications for Opioid Use Disorder (MOUD)

Extensive clinical trials and epidemiological studies confirm that MOUD reduces all-cause mortality by >50%, drastically reduces fatal overdoses, decreases illicit opioid use, suppresses criminal justice involvement, reduces HIV/HCV transmission, and significantly improves long-term treatment retention and quality of life.

+-----------------------------------------------------------------------------+
|                 THE THREE FDA-APPROVED MOUD MEDICATIONS                     |
|                                                                             |
|   1. METHADONE          --> Full Mu-Opioid Agonist (Daily OTP Dispensing)   |
|   2. BUPRENORPHINE      --> Partial Mu-Opioid Agonist (Office-Based / Depot)|
|   3. NALTREXONE (XR)    --> Full Mu-Opioid Antagonist (Monthly Vivitrol)    |
+-----------------------------------------------------------------------------+

Detailed Clinical Profiles of MOUD:

A. Methadone (Full Mu-Opioid Agonist)

• Mechanism: Synthetic full mu-opioid receptor agonist. When dosed adequately (typically 60–120 mg/day orally), methadone satisfies opioid receptor neuroadaptation, suppresses withdrawal symptoms, eliminates drug craving, and produces cross-tolerance (a "blockade effect" that blunts the euphoria of illicit opioids if consumed).
• Pharmacokinetics: Long elimination half-life (24 to 36 hours), allowing once-daily dosing. Steady-state plasma concentrations take 3 to 5 days to achieve; doses must be titrated slowly to prevent cumulative drug toxicity.
• Regulatory Framework: Under federal regulations (42 CFR Part 8), methadone for opioid use disorder may only be dispensed through SAMHSA-certified Opioid Treatment Programs (OTPs). That much has not changed — but the take-home rules did, substantially.
  • The 2024 Part 8 Final Rule (effective April 2, 2024, compliance date October 2, 2024) made the COVID-era flexibilities permanent and replaced rigid time-in-treatment thresholds with clinical judgment. An OTP practitioner now decides take-home eligibility using an overdose-prevention lens, shared decision-making with the patient, and the patient's specific circumstances, considering (rather than mechanically applying) the regulatory criteria such as absence of problematic substance use, regular clinic attendance, a stable and safe home environment, safe storage capability, and the balance of benefit and risk.
  • Practical effect: a patient may receive up to 7 take-home doses during the first 14 days of treatment and up to a 28-day supply after roughly a month of demonstrated stability. Counselors who tell clients they must "earn" take-homes through months of daily attendance are quoting a rule that no longer applies — though individual OTPs and state authorities may still impose stricter policies, and state law can be more restrictive than the federal floor.
• Adverse Effects & Safety: Sedation, constipation, sweating (diaphoresis), weight gain, and risk of QTc interval prolongation on electrocardiogram (EKG), which can lead to life-threatening torsades de pointes arrhythmias at high doses or when combined with other QTc-prolonging medications. High risk of fatal overdose during the first 1–2 weeks of induction if titrated too rapidly or combined with benzodiazepines/alcohol.

B. Buprenorphine (Partial Mu-Opioid Agonist & Kappa Antagonist)

• Mechanism: Partial agonist at the mu-opioid receptor and antagonist at the kappa-opioid receptor. Possesses exceptionally high receptor binding affinity (binds more tightly than heroin, morphine, or oxycodone) but low intrinsic efficacy.
• Ceiling Effect: Unlike full agonists, buprenorphine exhibits a pharmacological ceiling effect on respiratory depression. Beyond therapeutic doses (typically 16–24 mg/day sublingually), further dose increases produce no additional respiratory suppression, making fatal buprenorphine monotherapy overdoses extremely rare in opioid-tolerant adults.
• Formulations:
  • Buprenorphine / Naloxone (Suboxone, Zubsolv): Formulated in a 4:1 ratio (e.g., 8 mg buprenorphine / 2 mg naloxone sublingual film or tablet). When taken sublingually as prescribed, naloxone has minimal bioavailability (<5–10%) and exerts no clinical effect. However, if the medication is crushed and injected intravenously by an opioid-dependent person, the naloxone becomes fully active, blocking receptors and triggering severe precipitated withdrawal, thereby deterring intravenous diversion.
  • Buprenorphine Monotherapy (Subutex): Formulated without naloxone. Indicated primarily for pregnant individuals with OUD (to avoid theoretical fetal naloxone exposure) or individuals with documented severe adverse reactions to naloxone.
  • Extended-Release Injectable Buprenorphine (Sublocade, Brixadi): Monthly subcutaneous depot injections that provide continuous, stable plasma levels, eliminating daily adherence challenges and completely preventing medication diversion.
• Regulatory Transformation (The MAT Act): In December 2022, the Mainstreaming Addiction Treatment (MAT) Act was enacted into federal law, completely eliminating the federal "DATA 2000 X-Waiver" requirement. Any healthcare provider with a standard DEA registration (physicians, nurse practitioners, physician assistants) can now prescribe buprenorphine for OUD without patient census caps or specialized waiver training.
• Clinical Induction & Precipitated Withdrawal: Because buprenorphine has a higher binding affinity than full agonists but lower intrinsic activity, administering buprenorphine to an individual with full agonists occupying their mu-opioid receptors will cause buprenorphine to violently rip the full agonists off the receptors, dropping biological activity instantaneously and causing acute precipitated withdrawal.
  • Induction Rule: The client must be in active, objective withdrawal prior to the first dose, documented by a Clinical Opiate Withdrawal Scale (COWS) score ≥12 (moderate withdrawal: dilated pupils, sweating, tremors, yawning, gastrointestinal distress, piloerection [gooseflesh]).

C. Extended-Release Naltrexone (Vivitrol - Full Mu-Opioid Antagonist)

• Mechanism: Pure competitive mu-opioid receptor antagonist. Completely occupies and blocks opioid receptors, preventing any exogenous opioid from binding or producing euphoria/analgesia.
• Administration: Administered as an extended-release intramuscular gluteal injection of 380 mg once every 28 days (Vivitrol). An oral formulation (Revia, 50 mg daily) exists but suffers from poor long-term adherence.
• Mandatory Abstinence Prerequisite: Clients must be completely abstinent from all short-acting opioids for at least 7 to 10 days, and long-acting opioids (methadone/buprenorphine) for at least 10 to 14 days, prior to naltrexone initiation. A negative urine drug screen and a Naloxone Challenge Test must confirm zero physical opioid dependence. Administering naltrexone to an opioid-dependent client precipitates massive, immediate, severe withdrawal requiring emergency hospitalization.
• Critical Relapse Risk (Loss of Tolerance): Following naltrexone treatment, opioid receptor upregulation and loss of physiological opioid tolerance occur. If a client discontinues Vivitrol and relapses using their previous opioid dose, they face an extremely high risk of fatal respiratory arrest and death.

---

3. Emergency Opioid Overdose Reversal: Naloxone (Narcan)

Naloxone is a pure, short-acting, competitive mu-opioid receptor antagonist designed for the rapid emergency reversal of life-threatening opioid-induced respiratory depression.

+-----------------------------------------------------------------------------+
|                 EMERGENCY OPIOID OVERDOSE PROTOCOL (SAVE ME)                |
|                                                                             |
|   1. RECOGNIZE OVERDOSE:                                                    |
|      • Unresponsive / Unconscious                                           |
|      • Bradypnea (<8 breaths/min) or Apnea                                  |
|      • Pinpoint pupils (miosis)                                             |
|      • Cyanosis (blue/gray lips and nailbeds), death rattle choking sounds  |
|                                                                             |
|   2. ACTIVATE 911 (EMERGENCY MEDICAL SERVICES) IMMEDIATELY                  |
|                                                                             |
|   3. ADMINISTER NALOXONE:                                                   |
|      • Intranasal (Narcan 4 mg / Kloxxado 8 mg): Spray full dose into nostril|
|      • Intramuscular (IM 0.4-2 mg): Inject into outer thigh                 |
|                                                                             |
|   4. RESCUE BREATHING & RECOVERY POSITION:                                  |
|      • Provide rescue breaths (1 breath every 5 seconds)                    |
|      • If no response after 2-3 minutes, administer SECOND DOSE in other nos│
|      • Place in Recovery Position (on side) to prevent aspiration if emesis │
|                                                                             |
|   5. POST-REVIVAL MONITORING (MANDATORY):                                   |
|      • Naloxone half-life is 30-90 minutes; synthetic opioids (fentanyl,     |
|        methadone) have half-lives of hours to days.                         |
|      • Client is at high risk for RE-NARCOTIZATION (relapsing into coma)    |
|      • Continuous clinical/medical observation required for at least 2-4 hrs |
+-----------------------------------------------------------------------------+

---

4. Medications for Alcohol Use Disorder (AUD)

Pharmacotherapy for AUD is significantly underutilized despite robust clinical evidence. Three medications are FDA-approved for AUD: Acamprosate, Disulfiram, and Naltrexone.

Comprehensive AUD Pharmacotherapy Comparison Table

[!CAUTION] Disulfiram Safety Protocol: Never administer disulfiram until the client has been alcohol-free for at least 12 hours and has a confirmed Blood Alcohol Concentration (BAC) of 0.00. The disulfiram-ethanol reaction can occur for up to 14 days after the last dose of disulfiram due to the time required for the body to synthesize new aldehyde dehydrogenase enzymes.

---

5. Tobacco Use Disorder and Stimulant Pharmacotherapy

Tobacco Cessation Pharmacotherapies:

1. Nicotine Replacement Therapy (NRT):
   • Long-Acting: Transdermal nicotine patch (21 mg, 14 mg, 7 mg step-down) provides continuous, steady baseline nicotine levels to prevent withdrawal.
   • Short-Acting: Nicotine gum, lozenges, inhaler, and nasal spray deliver rapid nicotine spikes for acute craving relief.
   • Combination NRT: Combining the long-acting patch with a short-acting formulation (gum/lozenge) is significantly more effective than monotherapy.
2. Bupropion SR (Zyban / Wellbutrin): A norepinephrine-dopamine reuptake inhibitor (NDRI) and nicotinic antagonist. Alleviates nicotine cravings and post-cessation depression. Contraindicated in seizure disorders, anorexia, or bulimia due to lowering of the seizure threshold.
3. Varenicline (Chantix): An alpha-4-beta-2 nicotinic acetylcholine receptor partial agonist. Stimulates low-level dopamine release to mitigate cravings/withdrawal while competitively blocking inhaled nicotine from binding. Currently recognized as the most effective single-agent monotherapy for smoking cessation.

Stimulant Use Disorder Pharmacotherapy:

• Currently, there are NO FDA-approved medications for Cocaine Use Disorder or Methamphetamine Use Disorder.
• The gold-standard, evidence-based treatment for stimulant use disorders is Behavioral Contingency Management (CM), Cognitive Behavioral Therapy (CBT), and the Community Reinforcement Approach (CRA).
• Investigational Pharmacotherapies: Clinical trials (e.g., the NIH ADAPT-2 trial) demonstrate promising efficacy for combination Extended-Release Injectable Naltrexone (380 mg q3w) plus Oral Bupropion SR (450 mg/day) in reducing methamphetamine use.

---

6. Master Pharmacotherapy Reference Table

---

7. The Addiction Counselor's Role in Pharmacotherapy and Stigma Mitigation

Addiction counselors play a transformative role in the successful implementation of MAT/MOUD:

1. Dispelling Myths and Stigma: Counselors must actively educate clients, family members, community stakeholders, and 12-step groups that MOUD is an evidence-based medical treatment that corrects biological neurocircuitry derangements, comparable to insulin for diabetes or antihypertensives for hypertension.
2. Supporting Adherence and Monitoring: Regular tracking of medication compliance, managing minor side effects, encouraging honest communication with the prescribing provider, and reinforcing the synergistic combination of pharmacotherapy with psychosocial counseling.
3. Harm Reduction Advocacy: Ensuring every client receiving addiction services, regardless of primary substance, receives Naloxone (Narcan) training and a take-home kit, along with education on fentanyl test strips and overdose response.